Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
/in International Publications, IOZK VeröffentlichungenPosterpräsentation auf der Jahrestagung der Association for Cancer Immunotherapy
/in Glioblastoma, International Publications, IOZK bei Fachtagungen, IOZK VeröffentlichungenSynergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusStem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors
/in International Publications, IOZK VeröffentlichungenNeu in der Corona Ambulanz Köln: PCR Schnelltest
/in IOZK Aktuelles, IOZK In der Presse, IOZK MeldungenDNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival
/in Glioblastoma, International Publications, IOZK VeröffentlichungenImpaired DNA repair in mouse monocytes compared to macrophages and precursors
/in International Publications, IOZK VeröffentlichungenRandomized Controlled Immunotherapy Clinical Trials for GBM Challenged
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer